Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT(1B) and 5-HT(1D) receptors

European Journal of Pharmacology

Volumn 368, Issue 2-3, 1999, Pages 259-268

  Napier, Carolyn ^a   Stewart, Michael ^a   Melrose, Heather ^a   Hopkins, Brian ^a   McHarg, Aileen ^a   Wallis, Rob ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT(1B) receptor; 5 HT(1D) receptor; 5 ht(1f) receptor; 3H Eletriptan; 3H Sumatriptan

Indexed keywords

ELETRIPTAN; RECEPTOR SUBTYPE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUMATRIPTAN;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HELA CELL; HUMAN; HUMAN CELL; MIGRAINE; PRIORITY JOURNAL;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; COLD; COS CELLS; HELA CELLS; HUMANS; INDOLES; KINETICS; OXAZOLES; OXAZOLIDINONES; PIPERIDINES; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SUMATRIPTAN; TRIAZOLES; TRITIUM; TRYPTAMINES;

EID: 0033054234     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00026-6     Document Type: Article

References (52)

1. 1D-like receptor. J. Receptor Res. 13(1-4):1993;479-502.
2. Baldwin D., Rudge S. The role of serotonin in depression and anxiety. Int. Clin. Psychopharmacol. 9:1995;41-45. Suppl. 4.
3. 1D receptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;237-244.
4. 2C receptors. Br. J. Pharmacol. 115:1995;622-628.
5. Bouchelet I., Cohen Z., Case B., Séguléa P., Hamel Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50:1996;219-223.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
7. Connor H.E., Fenuik W., Beattie D.J., North P.C., Oxford A.W., Saynor D.A., Humphrey P.P.A. Naratriptan: biological profile in animals relevant to migraine. Cephalalgia. 17:1997;145-152.
8. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
9. 1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br. J. Pharmacol. 124:1998;283-290.
10. Ferro A., Longmore J., Hille R.G., Brown M.J. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vivo. Br. J. Pharmacol. 40:1995;245-251.
11. Gale J.D. Serotonergic mediation of vomiting. J. Pediatr. Gastroenterol. Nutr. 21:1995;S22-S28.
12. 4 receptors in guinea-pig and rat brain. Br. J. Pharmacol. 109:1993;618-624.
13. 1D-like' receptor in the dog saphenous vein. Cephalalgia. 16:1996;386.
14. 1B receptor. Eur. J. Pharmacol., in press.
15. 1Dβ receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol. 44:1993;242-246.
16. Hoyer M., Martin G. 5-HT receptor classification and nomenclature: towards a harmonisation with the human genome. Neuropharmacology. 36:1997;419-428.
17. 3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol. Pharmacol. 33:1988;303-309.
18. Humphrey P.P.A., Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci. 12:1991;444-446.
19. Eletriptan Steering Committee, Jackson N.C. A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia. 16:1996;368.
20. 3H] alniditan Mol. Pharmacol. 50:1996;1567-1580.
21. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new anti-migraine drugs. Cephalalgia. 17:1997;833-842.
22. Loric S., Maroteaux L., Kellerman O., Launay J.M. Functional serotonin-2B receptors are expressed by a teratocarcinoma-derived cell line during serotoninergic differentiation. Mol. Pharmacol. 47:1995;458-466.
23. Lucot J.B., Crampton G.H. 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol. Biochem. Behav. 33:1989;627-631.
24. 1B/1D agonist for migraine. Cephalalgia. 18:1997;4-14.
25. Martin, G.R., 1998. 5-Hydroxytryptamine receptors. In: The IUPHAR Compendium of Receptor Characterisation and Classification. IUPHAR Media, London, UK, pp. 167-185.
26. Meng C.Q. Migraine: current drug discovery. Curr. Med. Chem. 4:1997;385-404.
27. Monsma F.J., Chen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:1993;320-327.
28. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. 13:1992;307-311.
29. Motulsky H.J., Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25:1983;1-9.
30. 1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J. Biol. Chem. 269:1994;12954-12962.
31. Newman-Tancredi A., Conte C., Chaput C., Verrièle L., Audinoit-Bouchet V., Lochon S., Lavielle G., Millan M.J. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;682-688.
32. 1f receptor. Abstract Neurosci. 22, 528.12.
33. 1B/1D receptor agonists in the normotensive rat. Br. J. Pharmacol. 123:1998;205-214.
34. 1B/1D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology. 36:1997;499-512.
35. 1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;490-499.
36. 1f receptor agonist, in the neurogenic dural inflammation model of migraine pain. Society for Neurosci. 22:1996;1331.
37. 1f receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 61:1997;2117-2126.
38. Rance D.J., Atkinson F., James G. The pharmacokinetics of eletriptan (UK-116,044) in rats and dogs. Cephalalgia. 16:1996;387.
39. 1D receptor activation. Br. J. Pharmacol. 120:1997;211P.
40. 1D receptor agonists. Exp. Opin. Invest. Drugs. 5:1996;581-593.
41. 1D receptors Brit. J. Pharmacol. 120:1997;295P.
42. 1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol. 125:1998;202-208.
43. Eletriptan Steering Committee, Steiner T.J. Efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: results of a phase III study. Cephalalgia. 18:1998;385.
44. 3H] -mepyramine Br. J. Pharmacol. 94:1988;811-822.
45. Ullmer C., Schmuck K., Kalkman H.O., Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett. 370:1995;215-221.
46. 1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. 124:1998;1345-1354.
47. 35S ]GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur. J. Pharmacol. 117-124.
48. Weiland G.A., Molinoff P.B. Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 29:1981;313-330.
49. Wolff M.C., Benvenga M.J., Calligaro D.O., Fuller R.W., Gidda J.S., Hemrick-Luecke S., Lucot J.B., Nelson D.L., Overshiner C.D., Leander J.D. Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist. Drug Dev. Res. 40:1997;17-34.
50. 1B receptors. Br. J. Pharmacol. 120:1997;153-159.
51. 1D receptor subtype. Mol. Pharmacol. 40:1991;1036-1042.
52. 1Dβ receptor subtypes. Eur. J. Pharmacol. 291:1995;9-15.